Shares of Agenus Inc (NASDAQ:AGEN) , a biopharmaceutical company focused on developing novel immunotherapies to treat cancer and a number of other unmet diseases, tumbled by as much as 22% after partner GlaxoSmithKline (NYSE: GSK ) announced that its phase 3 MAGE-A3 cancer immunotherapeutic trial in non-small cell lung cancer (NSCLC) patients didn’t meet its first or second coprimary endpoint. Agenus Inc (NASDAQ:AGEN) stock performance was -11.63% in last session and finished the day at $3.80. Traded volume was 3,529,969 million shares in the last session and the average volume of the stock remained 899.92 million shares. The beta of the stock remained 1.68. Agenus Inc (NASDAQ:AGEN) insider ownership is 2.80%.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) had its price target upped by Wedbush from $27.00 to $32.00 in a research note issued to investors on Tuesday, American Banking & Market News reports. The firm currently has an outperform rating on the stock. La Jolla Pharmaceutical Company (NASDAQ:LJPC) dropped -11.57 percent to $13.60 yesterday on volume of 998,163.00 million shares. The intra-day range of the stock was $13.30 to $16.22. La Jolla Pharmaceutical Company (NASDAQ:LJPC) has a market capitalization of $82.42 million.

Shares of Durata Therapeutics (NASDAQ:DRTX) have earned a consensus recommendation of “Buy” from the eight analysts that are presently covering the company, American Banking and Market News reports. Durata Therapeutics Inc (NASDAQ:DRTX)’s stock on Mar20, 2014 reported a decrease of -6.97% to the closing price of $15.49. Its fifty two weeks range is $6.65 -$16.99. The total market capitalization recorded $412.66 million. The overall volume in the last trading session was 577,738 million shares. In its share capital, Durata Therapeutics Inc (NASDAQ:DRTX) has 26.62 million outstanding shares.

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) announced the pricing of its initial public offering of 2,837,400 ordinary shares at a public offering price of $13.50 per share, before underwriting discounts and commissions. Galmed has granted the underwriters an option for a period of 45 days to purchase, at the public offering price less the underwriting discount, up to 425,610 additional ordinary shares to cover over-allotments. On Thursday, shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) dropped -8.70% to close the day at $13.43.